Skip to main content
Edwards Lifesciences Logo
Edwards Lifesciences Logo

Secondary hidden

Humanizing Patient Hero image

As an interventional cardiologist, you can change someone’s future

With the EVOQUE transcatheter tricuspid valve replacement (TTVR) system, you may help tricuspid regurgitation (TR) patients return to a life they love.3

>20%

estimated mortality in patients with severe TR within 1 year of diagnosis4,5

95.3%

of patients achieved mild or less TR with EVOQUE TTVR at 1 year in the TRISCEND II Pivotal Trial3

18.4 points

improvement in KCCQ score for severe symptomatic TR patients with EVOQUE TTVR at 1 year compared to baseline in the TRISCEND II Pivotal Trial3†

91%

of patients achieved NYHA Class I/II at 1 year in the TRISCEND II Pivotal Trial3*

*Based on analysis of 1-year NYHA Class results in the EVOQUE TTVR group of the TRISCEND II trial (n=212).
†Based on analysis of 1-year Kansas City Cardiomyopathy Questionnaire results in the EVOQUE TTVR group of the TRISCEND II trial (n=211).

Data tells a story, but the real stories are with the patients

These stories are a tribute to the patients and physicians who - through these innovative products and procedures - are helping transform the way heart valve disease is treated.

‌

I was sleeping well. I was more active than I was before the procedure, and I was just very happy. Within two weeks I had worked up to my regular walking schedule.

-

Ed, treated with EVOQUE TTVR in August 2020

Mary patient image

You can't get that close to death and not having it change you. I feel my purpose now is to share my story and hopes.

-

Mary, treated with EVOQUE TTVR in January 2021

‌

I have my life back, and I’m not going to waste a minute of it.

-

Linda, treated with EVOQUE TTVR in September 2023

‌

I didn't think I'd get to this point and instead a miraculous thing happened.

-

Maria, treated with EVOQUE TTVR in February 2024

Learn how you can treat severe (or greater) tricuspid regurgitation and its debilitating symptoms with the EVOQUE tricuspid valve replacement system

The EVOQUE System thumbnail

The EVOQUE System

Learn more
EVOQUE system and TRISCEND II image

EVOQUE system and TRISCEND II clinical data summary

Download

** Based on analysis of 1-year Kansas City Cardiomyopathy Questionnaire results in the EVOQUE TTVR group of TRISCEND II trial (n=211).

References

  1. Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circ. 2019;140(7):196-206.
  2. Fender EA, Zack CJ, Nishimura RA. Isolated tricuspid regurgitation: Outcomes and therapeutic interventions. Heart. 2018;104(10):798-806.
  3. Hahn R, Makkar R, Thourani V, et al. Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. N Engl J Med. 2025;392:115-126.
  4. Chorin E, Rozenbaum Z, Topilsky Y, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging. 2020;21(2):157-165.
  5. Messika-Zeitoun D, Verta P, Gregson J, et al. Impact of tricuspid regurgitation on survival in patients with heart failure: A large electronic health record patient-level database analysis. Eur J Heart Fail. 2020;22(10):1803-1813.
Medical device for professional use

Medical device for professional use

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).